

**SEXUAL AND REPRODUCTIVE HEALTH (SRH) R&D MATRIX\***

		Basic research	Drugs	Vaccines (preventive)	Vaccines (therapeutic)	Diagnostics	Devices & combinations	
<b>Contraception</b>	On-demand <sup>1</sup>	-	✓	-	-	-	✓	
	Short-acting <sup>2</sup>	-	✓	-	-	-	✓	
	LARC <sup>3</sup>	-	✓	-	-	-	✓	
	Permanent <sup>4</sup>	-	✓	-	-	-	✓	
<b>HPV-related cervical cancer</b>		<u>Restricted</u>	<u>Restricted</u>	✓	<u>Restricted</u>	✓ <sup>5</sup>	-	
<b>Non-HIV sexually transmitted infections (STIs)</b>	Syphilis	<u>Restricted</u>	<u>Restricted</u>	✓	✓	-	-	
	Gonorrhoea	<u>Restricted</u>	<u>Restricted</u>	✓	✓	✓	-	
	Chlamydia	<u>Restricted</u>	-	✓	✓	✓	-	
	HSV-2	<u>Restricted</u>	✓	✓	✓	✓	-	
	HTLV-1	✓	✓	✓	✓	✓	-	
	Multiple STIs <sup>6</sup>	<u>Restricted</u>	<u>Restricted</u> <sup>7</sup>	✓	✓	✓	-	
	Other STIs <sup>8</sup>	<u>Restricted</u>	✓	✓	✓	✓	-	
<b>Post-partum haemorrhage (PPH)</b>		-	✓	-	-	-	<u>Restricted</u>	
<b>Pre-eclampsia</b>		<u>Restricted</u>	✓	-	-	✓	-	
<b>Other investment applicable to more than one sexual / reproductive health issue</b>								
<b>Multipurpose prevention technologies (MPTs)<sup>9</sup></b>			<b>Platform technologies</b>			<b>Core funding of an SRH R&amp;D organisation</b>		
Drugs	Devices & combinations		Adjuvants & immunomodulators		Delivery technologies			
✓	✓		✓		✓			

✓ denotes a category where a disease or product is included in the survey

Restricted denotes a category where only some investments are eligible

\* The survey scope for sexual and reproductive health (SRH) issues has not been defined using the same three-step filter used to determine the G-FINDER neglected disease survey scope. All relevant R&D activities for priority SRH issues were identified through extensive consultation with an expert advisory group. See the [G-FINDER sexual and reproductive health R&D scope document](#) for more detail.

<sup>1</sup> On-demand: methods that require action at the time of intercourse or pericoitally for efficacy (e.g. emergency contraception)

<sup>2</sup> Short-acting: methods that work for < 1 year but do not require action at the time of intercourse (e.g. injectable hormones)

<sup>3</sup> LARC: long-acting reversible contraceptives that work for ≥ 1 year (e.g. implants; IUDs)

<sup>4</sup> Permanent: irreversible methods

<sup>5</sup> Includes both diagnostics for HPV infection and diagnostics for cervical lesions

<sup>6</sup> Multiple STIs: two or more STIs, including but not limited to chlamydia, gonorrhoea, syphilis, and HIV

<sup>7</sup> Includes therapeutic drugs for the treatment of two or more STIs. For preventive drugs that address two or more STIs, please enter data under MPTs

<sup>8</sup> Other STIs: STIs that disproportionately affect populations in LMICs, including but not limited to trichomoniasis, chancroid, mycoplasma genitalium, lymphogranuloma venereum, and granuloma inguinale (donovanosis)

<sup>9</sup> MPTs: preventive drugs (including microbicides) and devices & combinations that address two or more SRH indications in the following combinations: Contraceptive + HIV; Contraceptive + STI; Contraceptive + STI + HIV; STI + HIV; and more than one STI. If a product has action on two or more SRH issues not covered in the combinations listed previously, please enter data under MPTs > other.